The activation of STING in tumor cells and DCs upregulates type I IFNs and interferon‐stimulated genes (ISGs), which promotes DC maturation and antigen cross‐priming while recruiting CD8+ T cells and NKs to the tumor site.[27] Moreover, ISGs can modulate antigen processing/presentation machinery (APM) to increase tumor immunogenicity.[27, 28] Thus, we examined the expression of ISGs, including IFN‐β and CXCL9, in the tumor tissue and found that the PmTriTNE@CDA‐treated group exhibited the highest ISG expression levels (Figure 5H,I). This evidence concerns the gene STING1 and neoplasm.